Dr Kaklamani on the Effects of VAF on Elacestrant Outcomes in ER Breast Cancer | OncLive
Dr Kaklamani on the Effects of VAF on Elacestrant Outcomes in ER Breast Cancer | OncLive
Dec 11, 2024
onclive.com
Ongoing Study of Adjuvant Elacestrant: Phase 3 ELEGANT | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Ongoing Study of Adjuvant Elacestrant: Phase 3 ELEGANT | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
9 months ago
targetedonc.com
Considering Elacestrant in ESR1 Breast Cancer After CDK4/6 Inhibition | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Considering Elacestrant in ESR1 Breast Cancer After CDK4/6 Inhibition | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Feb 17, 2025
targetedonc.com
Dr. Lin on the Advantage of Elacestrant in ESR1-Mutated Breast Cancer | OncLive
Dr. Lin on the Advantage of Elacestrant in ESR1-Mutated Breast Cancer | OncLive
Jun 14, 2022
onclive.com
The Role of Elacestrant in Breast Cancer | OncLive
The Role of Elacestrant in Breast Cancer | OncLive
Jan 30, 2024
onclive.com
Dr Lloyd on the Effects of ESR1 Mutations on Elacestrant Outcomes in HR+ Advanced Breast Cancer
2:35
Dr Lloyd on the Effects of ESR1 Mutations on Elacestrant Outcomes in HR+ Advanced Breast Cancer
342 viewsDec 13, 2024
YouTubeOncLive
Dr Bardia on the Investigation of Elacestrant vs Endocrine Therapy in ER Early Breast Cancer | OncLive
Dr Bardia on the Investigation of Elacestrant vs Endocrine Therapy in ER Early Breast Cancer | OncLive
1 month ago
onclive.com
ER metastatic breast cancer: Key insights on elacestrant from the latest EMERALD subgroup analyses
Mar 31, 2025
apple.com
0:57
Dr Kaklamani on the Effects of VAF on Elacestrant Outcomes in ER+ Breast Cancer
110 viewsDec 11, 2024
YouTubeOncLive
2:01
Real-World Data Reveal Longer PFS With Elacestrant in Breast Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Apr 9, 2025
targetedonc.com
The EMERALD Trial: Elacestrant Mechanism of Action, Study Design, and Outcomes | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Nov 9, 2022
targetedonc.com
All-Oral Elacestrant Combos Offer “Tremendous” Benefits in Breast Cancer | CancerNetwork
3 months ago
cancernetwork.com
Elacestrant + Targeted Therapy for ER+/HER2– Metastatic Breast Cancer: Early Phase Trial Findings | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1 month ago
targetedonc.com
EMERALD Phase 3 Trial of Elacestrant Versus Standard of Care Endocrine Therapy in Patients With ER /HER2- Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting | OncLive
Dec 22, 2022
onclive.com
20:05
ESR1 Mutation: The Need for & Role of Testing in ER+/ HER2- Advanced or Metastatic Breast Cancer
976 viewsSep 21, 2023
YouTubeCOR2ED The Heart of Medical Education
8:53
Elacestrant in ER+/HER2- mBC with ESR1-mut tumors: Overview of the EMERALD subgroup analyses
3K views11 months ago
YouTubeCOR2ED The Heart of Medical Education
0:50
FDA approves Elacestrant (Orserdu) for ER-positive, HER2-negative, ESR1-mutated breast cancer
1.4K viewsJan 29, 2023
YouTubemedXclusive Learning
3:07
The EMERALD Trial: Elacestrant in Patients with HR , HER2- Advanced Breast Cancer | OncLive
Feb 9, 2024
onclive.com
Tumore: elacestrant nuova terapia in aiuto a pazienti con carcinoma mammario
Jun 20, 2024
Il Sole 24 ORE
Dr. Bardia on Elacestrant in ER /HER2– Metastatic Breast Cancer | OncLive
Dec 8, 2022
onclive.com
1:44
Dr Rugo on Elacestrant-Based Combinations in ER /HER2– Metastatic Breast Cancer | OncLive
Dec 11, 2024
onclive.com
11:25
EMERALD Study Design and Results for Elacestrant  | OncLive
Jul 8, 2024
onclive.com
Imlunestrant vs Elacestrant: MOA and Clinical Trial Differences | Oncology Nursing News
6 months ago
oncnursingnews.com
Kaklamani on Elacestrant for CDK4/6 Inhibitor-Naive ER Breast Cancer Treatment | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Dec 12, 2024
targetedonc.com
6:07
Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER /HER2-, advanced breast cancer: a retrospective analysis using insurance claims in the United States | OncLive
Dec 18, 2024
onclive.com
Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting
May 9, 2023
marketscreener.com
EMERALD: Elacestrant in ER /HER2- Advanced Breast Cancer | OncLive
Jan 23, 2024
onclive.com
Dr O’Shaughnessy on the Impetus for the ELEGANT Study in High-Risk Breast Cancer | OncLive
2 months ago
onclive.com
EMERALD subgroup analysis: Elacestrant in endocrine-sensitive disease | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Nov 25, 2024
targetedonc.com
See more